United Therapeutics (UTHR) said Monday its subsidiary, Miromatrix's liver assist product, miroliverELAP, met the primary endpoint in a phase 1 study for patients with acute liver failure who were not transplant candidates.

The company said that the open-label study showed that five patients, who were not candidates for a liver transplant, were continuously treated with miroliverELAP for at least 44 hours and survived during treatment.

The drug developer said that no unexpected serious adverse events were reported over a 32-day follow-up, adding that full study results are expected to be published in H2 2026.